Animal anatomy

OneDigital Partners with Total Brain to Help Optimize Brain Capacities and Manage Risk Associated with Mental Health

Retrieved on: 
Monday, February 25, 2019

The Total Brain experience starts with a 20-minute clinically validated assessment using fun digital tasks to measure and benchmark 12 brain capacities encompassing emotion, feeling, cognition and self-control.

Key Points: 
  • The Total Brain experience starts with a 20-minute clinically validated assessment using fun digital tasks to measure and benchmark 12 brain capacities encompassing emotion, feeling, cognition and self-control.
  • Based on brain strengths and weaknesses, Total Brain further recommends science-backed digital brain exercises, breathing and meditations that help employees activate neuroplasticity and optimize themselves wherever they are on the spectrum from low to high brain performance.
  • "The Total Brain platform provides us all a unique opportunity to gain insights, manage risk, improve productivity and reduce healthcare costs."
  • Its SaaS platform helps people scientifically measure and optimize their brain capacities while managing the risk that they get impaired by common mental conditions.

Global Patient Scales Industry

Retrieved on: 
Wednesday, February 13, 2019

Table 78: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Patient Scales by Product Segment - Floor Scales, Infant & Baby Scales, Chair Scales, and Under Bed Scales Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2

Key Points: 
  • Table 78: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Patient Scales by Product Segment - Floor Scales, Infant & Baby Scales, Chair Scales, and Under Bed Scales Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2
    Table 79: Rest of Asia-Pacific Historic Review for Patient Scales by Product Segment - Floor Scales, Infant & Baby Scales, Chair Scales, and Under Bed Scales Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    Table 80: Rest of Asia-Pacific 14-Year Perspective for Patient Scales by Product Segment - Percentage Breakdown of Dollar Sales for Floor Scales, Infant & Baby Scales, Chair Scales, and Under Bed Scales Markets for Years 2009, 2017 & 2022 (includes corresponding Graph/Chart)
    Table 83: Latin American 14-Year Perspective for Patient Scales by Geographic Region - Percentage Breakdown of Dollar Sales for Brazil and Rest of Latin American Markets for Years 2009, 2017 & 2022 (includes corresponding Graph/Chart)
    Table 84: Latin American Recent Past, Current & Future Analysis for Patient Scales by Product Segment - Floor Scales, Infant & Baby Scales, Chair Scales, and Under Bed Scales Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2
    Table 85: Latin American Historic Review for Patient Scales by Product Segment - Floor Scales, Infant & Baby Scales, Chair Scales, and Under Bed Scales Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    Table 86: Latin American 14-Year Perspective for Patient Scales by Product Segment - Percentage Breakdown of Dollar Sales for Floor Scales, Infant & Baby Scales, Chair Scales, and Under Bed Scales Markets for Years 2009, 2017 & 2
    Table 87: Brazilian Recent Past, Current & Future Analysis for Patient Scales by Product Segment - Floor Scales, Infant & Baby Scales, Chair Scales, and Under Bed Scales Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    Table 88: Brazilian Historic Review for Patient Scales by Product Segment - Floor Scales, Infant & Baby Scales, Chair Scales, and Under Bed Scales Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2
    Table 89: Brazilian 14-Year Perspective for Patient Scales by Product Segment - Percentage Breakdown of Dollar Sales for Floor Scales, Infant & Baby Scales, Chair Scales, and Under Bed Scales Markets for Years 2009, 2017 & 2
    Table 90: Rest of Latin American Recent Past, Current & Future Analysis for Patient Scales by Product Segment - Floor Scales, Infant & Baby Scales, Chair Scales, and Under Bed Scales Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2
    Table 91: Rest of Latin American Historic Review for Patient Scales by Product Segment - Floor Scales, Infant & Baby Scales, Chair Scales, and Under Bed Scales Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    Table 92: Rest of Latin American 14-Year Perspective for Patient Scales by Product Segment - Percentage Breakdown of Dollar Sales for Floor Scales, Infant & Baby Scales, Chair Scales, and Under Bed Scales Markets for Years 2009, 2017 & 2022 (includes corresponding Graph/Chart)
    Table 93: Rest of World Recent Past, Current & Future Analysis for Patient Scales by Product Segment - Floor Scales, Infant & Baby Scales, Chair Scales, and Under Bed Scales Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2
    Table 94: Rest of World Historic Review for Patient Scales by Product Segment - Floor Scales, Infant & Baby Scales, Chair Scales, and Under Bed Scales Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    Table 95: Rest of World 14-Year Perspective for Patient Scales by Product Segment - Percentage Breakdown of Dollar Sales for Floor Scales, Infant & Baby Scales, Chair Scales, and Under Bed Scales Markets for Years 2009, 2017 & 2
    ReportLinker is an award-winning market research solution.
  • Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

Concert Pharmaceuticals Selected for Late-Breaking Oral Presentation of CTP-543 Phase 2 Data in Alopecia Areata at 2019 AAD Annual Meeting

Retrieved on: 
Monday, February 11, 2019

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that interim clinical data from its CTP-543 Phase 2 trial in alopecia areata has been selected for an oral presentation at the Late-Breaking Research Program during the American Academy of Dermatology (AAD) Annual Meeting being held March 1 - 5, 2019 in Washington, D.C.

Key Points: 
  • Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that interim clinical data from its CTP-543 Phase 2 trial in alopecia areata has been selected for an oral presentation at the Late-Breaking Research Program during the American Academy of Dermatology (AAD) Annual Meeting being held March 1 - 5, 2019 in Washington, D.C.
  • Deuterium modification of ruxolitinib was found to alter its human pharmacokinetics in ways which may enhance its use as a treatment for alopecia areata.
  • The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp.
  • Concert Pharmaceuticals Inc., theCoNCERT Pharmaceuticals Inc.logo and DCE Platform are registered trademarks ofConcert Pharmaceuticals, Inc. Jakafi is a registered trademark of Incyte Corporation.

Global Exoskeletons Market Outlook to 2026: Set to Record a CAGR of 46.1% - Analysis by Extremities Position, Type, Mobility, End-user and Geography - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 6, 2019

The "Global Exoskeletons Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2018 To 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Exoskeletons Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2018 To 2026" report has been added to ResearchAndMarkets.com's offering.
  • The exoskeletons market estimated to grow with a CAGR of 46.1% during the forecast period from 2018 to 2026.
  • Panasonic spokesperson Mio Yamanaka claims that the exoskeletons are all set to change the lives of people within 15 years.
  • However, robotics and heavy industrial manufacturers are facing fierce competition in order to introduce their best exoskeleton in the market.

VentureMed Group Names J. Robert Paulson Jr. Chief Executive Officer

Retrieved on: 
Tuesday, February 5, 2019

Gary Smith, the Company's CEO since 2014, will continue to serve as a member of the leadership team.

Key Points: 
  • Gary Smith, the Company's CEO since 2014, will continue to serve as a member of the leadership team.
  • The FLEX system provides acute luminal gain and increased vessel compliance which reduces the risk of flow-limiting dissections that require additional interventions.
  • Mr. Paulson joins the VentureMed Group from NxThera, where he served as president, CEO and board director from 2009 until the company's acquisition by Boston Scientific in 2018.
  • NxThera developed and commercialized a novel convective water vapor energy technology platform to treat enlarged prostates and other endourology conditions.

ThermoGenesis Corp Signs Strategic Supply Agreement with Orthohealing Center Management to Provide it's PXP® Point-of-Care System to Orthohealing Method™ Physician Members

Retrieved on: 
Friday, February 1, 2019

Haihong Zhu, ThermoGenesis' President, stated, "We are pleased to support OCM's rapidly expanding base of physician members who provide regenerative treatments for orthopaedic, sports medicine and pain management.

Key Points: 
  • Haihong Zhu, ThermoGenesis' President, stated, "We are pleased to support OCM's rapidly expanding base of physician members who provide regenerative treatments for orthopaedic, sports medicine and pain management.
  • We believe this agreement benefits both parties as our market penetration of the PXP system grows and Orthohealing Method members obtain cost-effective, 'closed system' sterile cell processing with our cutting-edge technology."
  • The PXP system is laboratory equipment that automates the harvest of a precise volume of cell concentrate from bone marrow aspirate in a sterile, "functionally closed" process at the point-of-care.
  • Processing data is captured using ThermoGenesis' proprietary DataTrak software to assist with Good Manufacturing Practice process monitoring and reporting information.

Total Brain is Launching TLEX Institute's Exclusive Breathing Exercises and Guided Meditations to Broaden the Means by which Users can Optimize their Own Brains

Retrieved on: 
Thursday, January 24, 2019

The new, exclusive breathing exercises and guided meditations are produced by TLEX Institute, a leader in mind-body restoration techniques for Fortune 100 companies.

Key Points: 
  • The new, exclusive breathing exercises and guided meditations are produced by TLEX Institute, a leader in mind-body restoration techniques for Fortune 100 companies.
  • "Having traditionally delivered our content in-person, we are thrilled to develop a digital version exclusively for Total Brain.
  • "Total Brain's optimization process is based on iterative assessments and exercises of the 12 core brain capacities in order to find what works for one's brain.
  • The proven restoration techniques from TLEX Institute add tremendous value and depth to the 29 brain trainings that Total Brain already has.

Total Brain is Launching TLEX Institute's Exclusive Breathing Exercises and Guided Meditations to Broaden the Means by which Users can Optimize their Own Brains

Retrieved on: 
Thursday, January 24, 2019

The new, exclusive breathing exercises and guided meditations are produced by TLEX Institute, a leader in mind-body restoration techniques for Fortune 100 companies.

Key Points: 
  • The new, exclusive breathing exercises and guided meditations are produced by TLEX Institute, a leader in mind-body restoration techniques for Fortune 100 companies.
  • "Having traditionally delivered our content in-person, we are thrilled to develop a digital version exclusively for Total Brain.
  • "Total Brain's optimization process is based on iterative assessments and exercises of the 12 core brain capacities in order to find what works for one's brain.
  • The proven restoration techniques from TLEX Institute add tremendous value and depth to the 29 brain trainings that Total Brain already has.

Introducing THICK HEAD for Men

Retrieved on: 
Wednesday, January 23, 2019

You may be suffering from HairanoiaWorry no more Introducing THICK HEAD, the world's first remedy to relieve the fear of hair loss.

Key Points: 
  • You may be suffering from HairanoiaWorry no more Introducing THICK HEAD, the world's first remedy to relieve the fear of hair loss.
  • Today marks the much-anticipated launch of THICK HEAD, a breakthrough brand poised to turn the men's hair loss market on its head.
  • Get your head in the game with the THICK HEAD system, which includes the following products:
    HEAD START Hair Loss Treatment & Regrowth System THICK HEAD's premiere starter kit, this first-of-its-kind, three-step system is designed to address active hair loss and promote hair regrowth.
  • (SRP: $9.95)
    THICK HEAD is now available at CVS, Rite Aid & www.thickhead.com
    Positioned to be the world's premiere men's hair growth system by offering superior formulas, boosting confidence and becoming the obvious choice for men with thinning hair, THICK HEAD is committed to changing the men's hair loss category.

Concert Pharmaceuticals Completes Enrollment of 12 mg Cohort in Phase 2a Trial of CTP-543 in Alopecia Areata

Retrieved on: 
Tuesday, January 22, 2019

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed patient enrollment of the final cohort evaluating 12 mg twice daily of CTP-543 in its Phase 2a trial for the treatment of moderate-to-severe alopecia areata.

Key Points: 
  • Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed patient enrollment of the final cohort evaluating 12 mg twice daily of CTP-543 in its Phase 2a trial for the treatment of moderate-to-severe alopecia areata.
  • Data from the Phase 2a trial including the 12 mg cohort is expected in the third quarter of 2019.
  • The Phase 2a trial is a double-blind, randomized, placebo-controlled, sequential dose trial to evaluate the safety and efficacy of CTP-543 in adult patients with moderate-to-severe alopecia areata.
  • In November 2018, Concert reported positive interim topline results from the first two cohorts (4 mg and 8 mg twice daily) in its Phase 2a trial.